Proactiveinvestors USA & Canada Antibe Therapeutics Inc https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Antibe Therapeutics Inc RSS feed en Sun, 17 Nov 2019 16:33:31 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Antibe Therapeutics is ready for a big push as it progresses pain management drug through clinical trials https://www.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html Mon, 21 Oct 2019 13:00:00 -0400 https://www.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html Antibe Therapeutics sees fiscal first quarter revenue rise thanks to higher sales in the United States https://www.proactiveinvestors.com/companies/news/901644/antibe-therapeutics-sees-fiscal-first-quarter-revenue-rise-thanks-to-higher-sales-in-the-united-states-901644.html Wed, 28 Aug 2019 13:35:00 -0400 https://www.proactiveinvestors.com/companies/news/901644/antibe-therapeutics-sees-fiscal-first-quarter-revenue-rise-thanks-to-higher-sales-in-the-united-states-901644.html Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain ‘proceeding well’ https://www.proactiveinvestors.com/companies/news/901552/antibe-therapeutics-phase-2b-study-of-flagship-drug-atb-346-to-treat-osteoarthritis-pain-proceeding-well-901552.html Tue, 27 Aug 2019 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/901552/antibe-therapeutics-phase-2b-study-of-flagship-drug-atb-346-to-treat-osteoarthritis-pain-proceeding-well-901552.html Antibe Therapeutics to sell units to raise money to further develop lead osteoarthritis drug https://www.proactiveinvestors.com/companies/news/224378/antibe-therapeutics-to-sell-units-to-raise-money-to-further-develop-lead-osteoarthritis-drug-224378.html Tue, 23 Jul 2019 21:00:00 -0400 https://www.proactiveinvestors.com/companies/news/224378/antibe-therapeutics-to-sell-units-to-raise-money-to-further-develop-lead-osteoarthritis-drug-224378.html Antibe Therapeutics is looking to the future after successful past year https://www.proactiveinvestors.com/companies/news/313988/antibe-therapeutics-is-looking-to-the-future-after-successful-past-year-13988.html Thu, 04 Jul 2019 16:26:00 -0400 https://www.proactiveinvestors.com/companies/news/313988/antibe-therapeutics-is-looking-to-the-future-after-successful-past-year-13988.html Antibe Therapeutics hosts successful annual and special general meeting https://www.proactiveinvestors.com/companies/news/223238/antibe-therapeutics-hosts-successful-annual-and-special-general-meeting-223238.html Tue, 02 Jul 2019 23:56:00 -0400 https://www.proactiveinvestors.com/companies/news/223238/antibe-therapeutics-hosts-successful-annual-and-special-general-meeting-223238.html Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346 https://www.proactiveinvestors.com/companies/news/222800/antibe-therapeutics-updates-on-phase-2-progress-of-lead-drug-atb-346-222800.html Tue, 25 Jun 2019 17:30:00 -0400 https://www.proactiveinvestors.com/companies/news/222800/antibe-therapeutics-updates-on-phase-2-progress-of-lead-drug-atb-346-222800.html Antibe Therapeutics CEO Dan Legault on why the multibillion-dollar NSAID market needs disruption https://www.proactiveinvestors.com/companies/news/221077/antibe-therapeutics-ceo-dan-legault-on-why-the-multibillion-dollar-nsaid-market-needs-disruption-221077.html Fri, 07 Jun 2019 20:08:00 -0400 https://www.proactiveinvestors.com/companies/news/221077/antibe-therapeutics-ceo-dan-legault-on-why-the-multibillion-dollar-nsaid-market-needs-disruption-221077.html Antibe Therapeutics targets opioids with post-op pain drug https://www.proactiveinvestors.com/companies/news/313615/antibe-therapeutics-targets-opioids-with-post-op-pain-drug-13615.html Wed, 05 Jun 2019 15:49:00 -0400 https://www.proactiveinvestors.com/companies/news/313615/antibe-therapeutics-targets-opioids-with-post-op-pain-drug-13615.html Antibe Therapeutics targets US$9 billion market with second pipeline drug ATB-352 for severe pain https://www.proactiveinvestors.com/companies/news/221396/antibe-therapeutics-targets-us9-billion-market-with-second-pipeline-drug-atb-352-for-severe-pain-221396.html Mon, 03 Jun 2019 15:10:00 -0400 https://www.proactiveinvestors.com/companies/news/221396/antibe-therapeutics-targets-us9-billion-market-with-second-pipeline-drug-atb-352-for-severe-pain-221396.html Antibe Therapeutics is a potential game changer in pain management https://www.proactiveinvestors.com/companies/news/313052/antibe-therapeutics-is-a-potential-game-changer-in-pain-management-13052.html Wed, 17 Apr 2019 20:09:00 -0400 https://www.proactiveinvestors.com/companies/news/313052/antibe-therapeutics-is-a-potential-game-changer-in-pain-management-13052.html Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology https://www.proactiveinvestors.com/companies/news/218693/antibe-therapeutic-s-phase-2b-trial-safety-results-for-pain-drug-atb-346-published-in-british-journal-of-pharmacology-218693.html Tue, 16 Apr 2019 12:23:00 -0400 https://www.proactiveinvestors.com/companies/news/218693/antibe-therapeutic-s-phase-2b-trial-safety-results-for-pain-drug-atb-346-published-in-british-journal-of-pharmacology-218693.html Antibe Therapeutics poised to disrupt the global pain management industry https://www.proactiveinvestors.com/companies/news/218520/antibe-therapeutics-poised-to-disrupt-the-global-pain-management-industry-218520.html Fri, 12 Apr 2019 20:00:00 -0400 https://www.proactiveinvestors.com/companies/news/218520/antibe-therapeutics-poised-to-disrupt-the-global-pain-management-industry-218520.html Antibe grants Kinght commercial rights for drug candidates https://www.proactiveinvestors.com/companies/news/119234/antibe-grants-kinght-commercial-rights-for-drug-candidates-119234.html Mon, 16 Nov 2015 14:32:00 -0500 https://www.proactiveinvestors.com/companies/news/119234/antibe-grants-kinght-commercial-rights-for-drug-candidates-119234.html Antibe Therapeutics plunges 80% on suspending lead drug’s phase I clinical trial https://www.proactiveinvestors.com/companies/news/105093/antibe-therapeutics-plunges-80-on-suspending-lead-drugs-phase-i-clinical-trial-59314.html Fri, 16 Jan 2015 14:22:00 -0500 https://www.proactiveinvestors.com/companies/news/105093/antibe-therapeutics-plunges-80-on-suspending-lead-drugs-phase-i-clinical-trial-59314.html Antibe Therapeutics seeks to fill market void with “ground-breaking” class of painkiller drugs https://www.proactiveinvestors.com/companies/news/97824/antibe-therapeutics-seeks-to-fill-market-void-with-ground-breaking-class-of-painkiller-drugs-48794.html Antibe Therapeutics is seeking to fill a vast market void with a “ground-breaking” class of painkiller drugs.  While the journey bringing the drug to market may be long and arduous, the end result appears to be well worth the toil, says president and CEO, Dan Legault. 

]]>
Wed, 09 Oct 2013 14:37:00 -0400 https://www.proactiveinvestors.com/companies/news/97824/antibe-therapeutics-seeks-to-fill-market-void-with-ground-breaking-class-of-painkiller-drugs-48794.html
Antibe Therapeutics completes second tranche of IPO https://www.proactiveinvestors.com/companies/news/96877/antibe-therapeutics-completes-second-tranche-of-ipo-47121.html Wed, 14 Aug 2013 19:08:00 -0400 https://www.proactiveinvestors.com/companies/news/96877/antibe-therapeutics-completes-second-tranche-of-ipo-47121.html